» Articles » PMID: 39222570

Relationships Between Regional Burden of Tau Pathology and Age at Death and Disease Duration in PSP

Abstract

Background: A definitive diagnosis of progressive supranuclear palsy (PSP) can only be established through neuropathological evaluations where four cardinal tau lesions are identified. Relationships between regional tau burden and disease duration/age at death is unclear.

Objective: To investigate relationships between tau burden in different brain regions and disease duration and age at death in PSP and determine whether association are influenced by PSP subtype (subcortical/cortical) or co-pathologies.

Methods: We identified 45 patients with definite PSP who were evaluated at Mayo Clinic between 2009 and 2023, died and underwent histopathological evaluation. We performed semi-quantitative lesion count for each of four cardinal lesions (pretangles/globose neurofibrillary tangles, threads, tufted astrocytes, and coiled bodies) across 10 brain regions. We fit Bayesian linear hierarchical regression models to estimate the relationship between total pathological burden, and disease duration and age at death by region and the influence of subtype and co-pathologies.

Results: Of the 45 patients, 18 (40 %) were female. Median age at death was 75 (56-87) years and median disease duration was 8 (3,15) years. Younger age at death was associated with greater total tau burden in the pallidum, red nucleus, striatum, and subthalamic nucleus (all p ≤ 0.01). Shorter disease duration was associated with greater total tau burden in the red nucleus (p = 0.05). There was no evidence for a difference in association between lesion types. PSP subtype and co-pathologies did not influence associations.

Conclusions: The findings from this study suggest that age and disease duration influence burden of tau pathology in subcortical regions in PSP.

References
1.
Whitwell J, Stevens C, Duffy J, Clark H, Machulda M, Strand E . An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant. Mov Disord Clin Pract. 2019; 6(6):452-461. PMC: 6660227. DOI: 10.1002/mdc3.12796. View

2.
Kovacs G, Ferrer I, Grinberg L, Alafuzoff I, Attems J, Budka H . Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2015; 131(1):87-102. PMC: 4879001. DOI: 10.1007/s00401-015-1509-x. View

3.
Carlos A, Tosakulwong N, Weigand S, Buciuc M, Ali F, Clark H . Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Commun. 2022; 4(3):fcac108. PMC: 9155234. DOI: 10.1093/braincomms/fcac108. View

4.
Greenland S . Bayesian perspectives for epidemiological research. II. Regression analysis. Int J Epidemiol. 2007; 36(1):195-202. DOI: 10.1093/ije/dyl289. View

5.
Warren N, Piggott M, Lees A, Burn D . The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2006; 78(6):571-5. PMC: 2077948. DOI: 10.1136/jnnp.2006.099937. View